研究用フローサイトと理化学分析

世界のリサーチ分野のお客さまへ先端の検査装置のご案内です。

お問い合わせはこちら

sysmex

研究用フローサイトと理化学分析sysmex

CyFlow CD255 Low Endotoxin

品番 AE247732
抗体名 Anti-Hu CD255 LOW END,CARL-1
包装単位 0.1 mg
濃度 1 mg/ml
容量 0.1 ml
関連製品
(アイソタイプコントロール)
-
反応性|交差吸着 Human レーザー
抗原 CD255, TWEAK 最大蛍光波長 -
クローン CARL-1 最大励起波長 -
ホスト Mouse 標識/Format Low Endotoxin
アイソタイプ IgG3 研究分野 Immunophenotyping | Apoptosis
クローナリティ monoclonal 用途

Flow cytometry
Immunohistochemistry
Functional assays

Anti-Hu CD255 LOW END,CARL-1

特異性

The mouse monoclonal antibody CARL-1 recognizes CD255 (TWEAK) antigen, a type II transmembrane protein of the TNF superfamily able to weakly induce apoptosis in many cell types.

抗原情報

CD255 (TWEAK; TNF-related weak inducer of apoptosis), a type II transmembrane protein expressed as membrane-bound and secreted form, can induce apoptosis in many tissues and cell lines through its receptor CD266 (TWEAK R). On the other hand, in endothelial cells this interaction can induce proliferation and promote angiogenesis including neovascularization of tumors. CD255 can act in a juxtacrine manner to initiate cellular responses, and induces secretion of pro-inflammatory cytokines. Besides CD266, CD255 may also bind to DR3.

利用方法

保存方法

Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.

安定性情報

Do not use after expiration date stamped on vial label.

レファレンス

• Brown SA, Ghosh A, Winkles JA: Full‑length, membrane‑anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF‑kappaB pathway. J·Biol·Chem. 2010·Jun·4; 285(23):17432‑41. <·PMID:·20385556·>
• Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T: Proinflammatory effects of tumour necrosis factor‑like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin·Exp·Immunol. 2006·Dec; 146(3):540‑9. <·PMID:·17100776·>
• Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor‑inducible 14 mediates multiple pathways of TWEAK‑induced cell death. J·Immunol. 2003·Jan·1; 170(1):341‑8. <·PMID:·12496418·>
• Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H: Involvement of TWEAK in interferon gamma‑stimulated monocyte cytotoxicity. J·Exp·Med. 2000·Nov·6; 192(9):1373‑80. <·PMID:·11067885·>
• Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S: TWEAK induces NF‑kappaB2 p100 processing and long lasting NF‑kappaB activation. J·Biol·Chem. 2003·Sep·19; 278(38):36005‑12. <·PMID:·12840022·>
• Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp·Ther·Med. 2011·Jan; 2(1):103‑108. <·PMID:·22977477·>